Just this week.... in pharmaceutical/biomedical land...there has been a lot of activity. It will pale in comparison to what possibilities there are for a game changer. But, these little appetizers may whet your curiosity...as the acquisition environment heats up.
Amylin Said to Have Spurned $3.5 Billion Bristol Bid
Mar 28, 2012 10:57 AM CTWed Mar 28 15:57:03 GMT 2012
Amylin Pharmaceuticals Inc. (AMLN), the maker of the diabetes drug Bydureon, rejected a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb Co. (BMY) earlier this year, according to two people with knowledge of the matter.
Bristol-Myers proposed an acquisition at $22 a share in a letter to Amylin, which the board turned down last month, said the people, who declined to be identified because the approach was private. The price is 43 percent more than Amylin’s closing stock price of $15.39 yesterday. The $3.5 billion figure, based on 160.8 million Amylin shares outstanding, excludes debt.
Ista snapped up by Bausch & Lomb for $500 mln…Bausch & Lomb's Saunders said he expects to file for a marketing approval with the U.S. Food and Drug Administration for Ista's experimental eye inflammation drug Prolensa later this year.
California-based Ista, which has annual revenue of about $130 million, is currently conducting efficacy studies on Prolensa in the late stage.
Valeant To Buy Russian Specialty Pharma Company For $180 Mln March 26, 2012, 9:44 a.m. ET